 | • レポートコード：MRC2-11QY11251 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は多発性骨髄腫に対するCAR-T細胞療法のグローバル市場について調査・分析したレポートです。種類別（単剤療法、併用療法）市場規模、用途別（多発性骨髄腫、難治性/再発性多発性骨髄腫）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別多発性骨髄腫に対するCAR-T細胞療法の競争状況、市場シェア ・世界の多発性骨髄腫に対するCAR-T細胞療法市場：種類別市場規模 2015年-2020年（単剤療法、併用療法） ・世界の多発性骨髄腫に対するCAR-T細胞療法市場：種類別市場規模予測 2021年-2026年（単剤療法、併用療法） ・世界の多発性骨髄腫に対するCAR-T細胞療法市場：用途別市場規模 2015年-2020年（多発性骨髄腫、難治性/再発性多発性骨髄腫） ・世界の多発性骨髄腫に対するCAR-T細胞療法市場：用途別市場規模予測 2021年-2026年（多発性骨髄腫、難治性/再発性多発性骨髄腫） ・北米の多発性骨髄腫に対するCAR-T細胞療法市場分析：米国、カナダ ・ヨーロッパの多発性骨髄腫に対するCAR-T細胞療法市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの多発性骨髄腫に対するCAR-T細胞療法市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の多発性骨髄腫に対するCAR-T細胞療法市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの多発性骨髄腫に対するCAR-T細胞療法市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Juno Therapeutics、Kite Pharma、Novartis、Collectis ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual’s own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma.
The increasing number of collaborations or licensing agreements between companies and research institute, will induce the involvement of more investors in this area. Car T-cell therapy for multiple myeloma has identified that most of the pipeline molecules in multiple myeloma are currently in the pre-clinical development stage. KMA.CAR-T the drug is under development by the company HaemaLogiX. This monotherapy drug is currently in the pre-clinical stage and the company has already signed an agreement with Westmead Institute for Medical Research.
Market Analysis and Insights: Global CAR T-Cell Therapy for Multiple Myeloma Market
The global CAR T-Cell Therapy for Multiple Myeloma market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global CAR T-Cell Therapy for Multiple Myeloma Scope and Market Size
CAR T-Cell Therapy for Multiple Myeloma market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global CAR T-Cell Therapy for Multiple Myeloma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Juno Therapeutics
Kite Pharma
Novartis
Collectis
…
Market segment by Type, the product can be split into
Monotherapy
Combination Therapy
Market segment by Application, split into
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by CAR T-Cell Therapy for Multiple Myeloma Revenue
1.4 Market by Type
1.4.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Monotherapy
1.4.3 Combination Therapy
1.5 Market by Application
1.5.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Application: 2020 VS 2026
1.5.2 Multiple Myeloma
1.5.3 Refractory or Relapsed Multiple Myeloma
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Perspective (2015-2026)
2.2 Global CAR T-Cell Therapy for Multiple Myeloma Growth Trends by Regions
2.2.1 CAR T-Cell Therapy for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 CAR T-Cell Therapy for Multiple Myeloma Historic Market Share by Regions (2015-2020)
2.2.3 CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 CAR T-Cell Therapy for Multiple Myeloma Market Growth Strategy
2.3.6 Primary Interviews with Key CAR T-Cell Therapy for Multiple Myeloma Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Market Size
3.1.1 Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Revenue (2015-2020)
3.1.2 Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Players (2015-2020)
3.1.3 Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Concentration Ratio
3.2.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy for Multiple Myeloma Revenue in 2019
3.3 CAR T-Cell Therapy for Multiple Myeloma Key Players Head office and Area Served
3.4 Key Players CAR T-Cell Therapy for Multiple Myeloma Product Solution and Service
3.5 Date of Enter into CAR T-Cell Therapy for Multiple Myeloma Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global CAR T-Cell Therapy for Multiple Myeloma Historic Market Size by Type (2015-2020)
4.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)
5.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
6.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in North America (2019-2020)
6.3 North America CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
6.4 North America CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)
7 Europe
7.1 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
7.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in Europe (2019-2020)
7.3 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
7.4 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)
8 China
8.1 China CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
8.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in China (2019-2020)
8.3 China CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
8.4 China CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)
9 Japan
9.1 Japan CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
9.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in Japan (2019-2020)
9.3 Japan CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
9.4 Japan CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
10.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
10.4 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)
11 India
11.1 India CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
11.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in India (2019-2020)
11.3 India CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
11.4 India CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Size (2015-2020)
12.2 CAR T-Cell Therapy for Multiple Myeloma Key Players in Central & South America (2019-2020)
12.3 Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020)
12.4 Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Juno Therapeutics
13.1.1 Juno Therapeutics Company Details
13.1.2 Juno Therapeutics Business Overview
13.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Introduction
13.1.4 Juno Therapeutics Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020))
13.1.5 Juno Therapeutics Recent Development
13.2 Kite Pharma
13.2.1 Kite Pharma Company Details
13.2.2 Kite Pharma Business Overview
13.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Introduction
13.2.4 Kite Pharma Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020)
13.2.5 Kite Pharma Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Introduction
13.3.4 Novartis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Collectis
13.4.1 Collectis Company Details
13.4.2 Collectis Business Overview
13.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Introduction
13.4.4 Collectis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020)
13.4.5 Collectis Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. CAR T-Cell Therapy for Multiple Myeloma Key Market Segments
Table 2. Key Players Covered: Ranking by CAR T-Cell Therapy for Multiple Myeloma Revenue
Table 3. Ranking of Global Top CAR T-Cell Therapy for Multiple Myeloma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global CAR T-Cell Therapy for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Monotherapy
Table 6. Key Players of Combination Therapy
Table 7. Global CAR T-Cell Therapy for Multiple Myeloma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Regions (2015-2020)
Table 11. Global CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. CAR T-Cell Therapy for Multiple Myeloma Market Growth Strategy
Table 17. Main Points Interviewed from Key CAR T-Cell Therapy for Multiple Myeloma Players
Table 18. Global CAR T-Cell Therapy for Multiple Myeloma Revenue by Players (2015-2020) (Million US$)
Table 19. Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Players (2015-2020)
Table 20. Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR T-Cell Therapy for Multiple Myeloma as of 2019)
Table 21. Global CAR T-Cell Therapy for Multiple Myeloma by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players CAR T-Cell Therapy for Multiple Myeloma Product Solution and Service
Table 24. Date of Enter into CAR T-Cell Therapy for Multiple Myeloma Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 27. Global CAR T-Cell Therapy for Multiple Myeloma Market Size Share by Type (2015-2020)
Table 28. Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Type (2021-2026)
Table 29. Global CAR T-Cell Therapy for Multiple Myeloma Market Size Share by Application (2015-2020)
Table 30. Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 31. Global CAR T-Cell Therapy for Multiple Myeloma Market Size Share by Application (2021-2026)
Table 32. North America Key Players CAR T-Cell Therapy for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 33. North America Key Players CAR T-Cell Therapy for Multiple Myeloma Market Share (2019-2020)
Table 34. North America CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 35. North America CAR T-Cell Therapy for Multiple Myeloma Market Share by Type (2015-2020)
Table 36. North America CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 37. North America CAR T-Cell Therapy for Multiple Myeloma Market Share by Application (2015-2020)
Table 38. Europe Key Players CAR T-Cell Therapy for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players CAR T-Cell Therapy for Multiple Myeloma Market Share (2019-2020)
Table 40. Europe CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 41. Europe CAR T-Cell Therapy for Multiple Myeloma Market Share by Type (2015-2020)
Table 42. Europe CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 43. Europe CAR T-Cell Therapy for Multiple Myeloma Market Share by Application (2015-2020)
Table 44. China Key Players CAR T-Cell Therapy for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 45. China Key Players CAR T-Cell Therapy for Multiple Myeloma Market Share (2019-2020)
Table 46. China CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 47. China CAR T-Cell Therapy for Multiple Myeloma Market Share by Type (2015-2020)
Table 48. China CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 49. China CAR T-Cell Therapy for Multiple Myeloma Market Share by Application (2015-2020)
Table 50. Japan Key Players CAR T-Cell Therapy for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players CAR T-Cell Therapy for Multiple Myeloma Market Share (2019-2020)
Table 52. Japan CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 53. Japan CAR T-Cell Therapy for Multiple Myeloma Market Share by Type (2015-2020)
Table 54. Japan CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 55. Japan CAR T-Cell Therapy for Multiple Myeloma Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players CAR T-Cell Therapy for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players CAR T-Cell Therapy for Multiple Myeloma Market Share (2019-2020)
Table 58. Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Share by Type (2015-2020)
Table 60. Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Share by Application (2015-2020)
Table 62. India Key Players CAR T-Cell Therapy for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 63. India Key Players CAR T-Cell Therapy for Multiple Myeloma Market Share (2019-2020)
Table 64. India CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 65. India CAR T-Cell Therapy for Multiple Myeloma Market Share by Type (2015-2020)
Table 66. India CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 67. India CAR T-Cell Therapy for Multiple Myeloma Market Share by Application (2015-2020)
Table 68. Central & South America Key Players CAR T-Cell Therapy for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players CAR T-Cell Therapy for Multiple Myeloma Market Share (2019-2020)
Table 70. Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Share by Type (2015-2020)
Table 72. Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Share by Application (2015-2020)
Table 74. Juno Therapeutics Company Details
Table 75. Juno Therapeutics Business Overview
Table 76. Juno Therapeutics Product
Table 77. Juno Therapeutics Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020) (Million US$)
Table 78. Juno Therapeutics Recent Development
Table 79. Kite Pharma Company Details
Table 80. Kite Pharma Business Overview
Table 81. Kite Pharma Product
Table 82. Kite Pharma Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020) (Million US$)
Table 83. Kite Pharma Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Product
Table 87. Novartis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020) (Million US$)
Table 88. Novartis Recent Development
Table 89. Collectis Company Details
Table 90. Collectis Business Overview
Table 91. Collectis Product
Table 92. Collectis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2015-2020) (Million US$)
Table 93. Collectis Recent Development
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Type: 2020 VS 2026
Figure 2. Monotherapy Features
Figure 3. Combination Therapy Features
Figure 4. Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Application: 2020 VS 2026
Figure 5. Multiple Myeloma Case Studies
Figure 6. Refractory or Relapsed Multiple Myeloma Case Studies
Figure 7. CAR T-Cell Therapy for Multiple Myeloma Report Years Considered
Figure 8. Global CAR T-Cell Therapy for Multiple Myeloma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 9. Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Regions: 2020 VS 2026
Figure 10. Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Regions (2021-2026)
Figure 11. Porter's Five Forces Analysis
Figure 12. Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Players in 2019
Figure 13. Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR T-Cell Therapy for Multiple Myeloma as of 2019
Figure 14. The Top 10 and 5 Players Market Share by CAR T-Cell Therapy for Multiple Myeloma Revenue in 2019
Figure 15. North America CAR T-Cell Therapy for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 16. Europe CAR T-Cell Therapy for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. China CAR T-Cell Therapy for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Japan CAR T-Cell Therapy for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. India CAR T-Cell Therapy for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Central & South America CAR T-Cell Therapy for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Bottom-up and Top-down Approaches for This Report
Figure 23. Data Triangulation
Figure 24. Key Executives Interviewed
多発性骨髄腫治療の世界市場（～2026年） Multiple myeloma is a cancer formed due to malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. Plasma cells helps to fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to acc…- 多発性骨髄腫治療薬の世界市場（～2026年） Multiple Myeloma (MM) is a haematological malignancy considered by the propagation of plasma cells in the bone marrow. The disease is incurable; though over the few years there have been substantial developments in therapy, determined by a greater understanding of pathophysiology. Multiple myeloma i…
- 多発性硬化症における幹細胞治療の世界市場（～2026年） Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision,…
- 変形性関節症における幹細胞治療の世界市場（～2026年） Osteoarthritis is one of the chronic conditions for joints which results in the breakdown and eventual loss of the cartilage of one or more joints. This can affect joints including hips, lower back, neck, small joints of the fingers, and the base of the thumb and big toe. The expected growth is beca…
- 多発性硬化症治療の世界市場（～2026年） Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and somet…